IBDEI0IW ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8503,2)
 ;;=^5001790
 ;;^UTILITY(U,$J,358.3,8504,0)
 ;;=C92.00^^39^401^8
 ;;^UTILITY(U,$J,358.3,8504,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8504,1,3,0)
 ;;=3^Acute Myeloblastic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,8504,1,4,0)
 ;;=4^C92.00
 ;;^UTILITY(U,$J,358.3,8504,2)
 ;;=^5001789
 ;;^UTILITY(U,$J,358.3,8505,0)
 ;;=C92.61^^39^401^9
 ;;^UTILITY(U,$J,358.3,8505,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8505,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,In Remission
 ;;^UTILITY(U,$J,358.3,8505,1,4,0)
 ;;=4^C92.61
 ;;^UTILITY(U,$J,358.3,8505,2)
 ;;=^5001808
 ;;^UTILITY(U,$J,358.3,8506,0)
 ;;=C92.60^^39^401^10
 ;;^UTILITY(U,$J,358.3,8506,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8506,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ 11q23-Abnormality,Not in Remission
 ;;^UTILITY(U,$J,358.3,8506,1,4,0)
 ;;=4^C92.60
 ;;^UTILITY(U,$J,358.3,8506,2)
 ;;=^5001807
 ;;^UTILITY(U,$J,358.3,8507,0)
 ;;=C92.A1^^39^401^11
 ;;^UTILITY(U,$J,358.3,8507,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8507,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,In Remission
 ;;^UTILITY(U,$J,358.3,8507,1,4,0)
 ;;=4^C92.A1
 ;;^UTILITY(U,$J,358.3,8507,2)
 ;;=^5001814
 ;;^UTILITY(U,$J,358.3,8508,0)
 ;;=C92.A0^^39^401^12
 ;;^UTILITY(U,$J,358.3,8508,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8508,1,3,0)
 ;;=3^Acute Myeloid Leukemia w/ Multilin Dysplasia,Not in Remission
 ;;^UTILITY(U,$J,358.3,8508,1,4,0)
 ;;=4^C92.A0
 ;;^UTILITY(U,$J,358.3,8508,2)
 ;;=^5001813
 ;;^UTILITY(U,$J,358.3,8509,0)
 ;;=C92.51^^39^401^13
 ;;^UTILITY(U,$J,358.3,8509,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8509,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,8509,1,4,0)
 ;;=4^C92.51
 ;;^UTILITY(U,$J,358.3,8509,2)
 ;;=^5001805
 ;;^UTILITY(U,$J,358.3,8510,0)
 ;;=C92.50^^39^401^14
 ;;^UTILITY(U,$J,358.3,8510,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8510,1,3,0)
 ;;=3^Acute Myelomonocytic Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,8510,1,4,0)
 ;;=4^C92.50
 ;;^UTILITY(U,$J,358.3,8510,2)
 ;;=^5001804
 ;;^UTILITY(U,$J,358.3,8511,0)
 ;;=C94.40^^39^401^17
 ;;^UTILITY(U,$J,358.3,8511,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8511,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,Not in Remission
 ;;^UTILITY(U,$J,358.3,8511,1,4,0)
 ;;=4^C94.40
 ;;^UTILITY(U,$J,358.3,8511,2)
 ;;=^5001843
 ;;^UTILITY(U,$J,358.3,8512,0)
 ;;=C94.42^^39^401^15
 ;;^UTILITY(U,$J,358.3,8512,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8512,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Relapse
 ;;^UTILITY(U,$J,358.3,8512,1,4,0)
 ;;=4^C94.42
 ;;^UTILITY(U,$J,358.3,8512,2)
 ;;=^5001845
 ;;^UTILITY(U,$J,358.3,8513,0)
 ;;=C94.41^^39^401^16
 ;;^UTILITY(U,$J,358.3,8513,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8513,1,3,0)
 ;;=3^Acute Panmyelosis w/ Myelofibrosis,In Remission
 ;;^UTILITY(U,$J,358.3,8513,1,4,0)
 ;;=4^C94.41
 ;;^UTILITY(U,$J,358.3,8513,2)
 ;;=^5001844
 ;;^UTILITY(U,$J,358.3,8514,0)
 ;;=D62.^^39^401^18
 ;;^UTILITY(U,$J,358.3,8514,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8514,1,3,0)
 ;;=3^Acute Posthemorrhagic Anemia
 ;;^UTILITY(U,$J,358.3,8514,1,4,0)
 ;;=4^D62.
 ;;^UTILITY(U,$J,358.3,8514,2)
 ;;=^267986
 ;;^UTILITY(U,$J,358.3,8515,0)
 ;;=C92.41^^39^401^19
 ;;^UTILITY(U,$J,358.3,8515,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8515,1,3,0)
 ;;=3^Acute Promyelocytic Leukemia,In Remission
